Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 25, 2016 (11 years ago)

All sucralfate Products

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Processing Controls

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

All sucralfate Products, Rx Only, Compounded by RELIABLE DRUG/RELIABLE COMPOUNDING PHARMACY, 801 Irving St., SAN FRANCISCO, CA 94122.

Drug: Sucralfate

Recalling firm
Reliable Rexall-A Compounding Pharmacy
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1122-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Sucralfate recalls

See all
Class II · Moderate risk

Sucralfate Tablets

CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Ongoing cGMP deviation Amerisource Health Services LLC NDC 60687-695-01 D-0027-2026
Class II · Moderate risk

Sucralfate Tablets

CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Ongoing cGMP deviation Amerisource Health Services LLC NDC 60687-695-01 D-0598-2025
Class II · Moderate risk

Sucralfate Tablets

CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Ongoing cGMP deviation Nostrum Laboratories, Inc. NDC 29033-0003-01 D-0547-2025

Other recalls by Reliable Rexall-A Compounding Pharmacy

All 2016 recalls
Class II · Moderate risk

All Malarone

Lack of Processing Controls

Terminated cGMP deviation Reliable Rexall-A Compounding Pharmacy D-1136-2016